Turkey

Sultans Blue Mosque by Levent Coskun with CC

Turkey, land of the Seljuks and Ottomans, is a coun­try at the gate­way of mod­ern­isa­tion between Europe and Asia. Turkey has been a com­pet­i­tive coun­try since the beginning of civilisation—and as today’s Pharma indus­try gains momentum there, the coun­try promises qual­ity partnerships, rigorous challenges and, yes, even more competition.

Turkey has taken many steps towards a work­ing health­care sys­tem. The health­care sys­tem in Turkey has entered a long period of devel­op­ment under the 2003-2013 Health Trans­for­ma­tion Pro­gram. The pur­pose of the pro­gram is to increase the qual­ity and effi­ciency of the health­care sys­tem and enhance access to health­care facil­i­ties.

Accord­ing to the Phar­ma­ceu­ti­cal Man­u­fac­tur­ers Asso­ci­a­tion of Turkey (IEIS), the Turk­ish phar­ma­ceu­ti­cal mar­ket was worth around US $11.6 bil­lion in 2012, up from US $4 bil­lion in 2003, grow­ing by a compound annual growth rate (CAGR) of 12.6%. Turkey has nearly 300 local phar­ma­ceu­ti­cal com­pa­nies and 49 man­u­fac­tur­ing com­pa­nies, with 13 of those belonging to for­eign investors. The indus­try employs approx­i­mately 25,000 peo­ple.

There are many OTC, Med­ical Device and Food Sup­ple­ment com­pa­nies sell­ing West­ern Euro­pean prod­ucts to huge suc­cess. The Turkish Gen­eral Direc­torate of Phar­ma­ceu­ti­cals and Phar­macy, a divi­sion of the Min­istry of Health, is in charge of reg­u­la­tion and con­trol of phar­ma­ceu­ti­cal prices. Man­u­fac­tur­ers and importers are obliged to apply to the Min­istry of Health for the autho­risa­tion of new prod­uct prices, as well as for price increases and decreases.

The most fre­quent causes of death in Turkey are, in order of fre­quency, can­cer, heart dis­ease and cerebral-vascular dis­eases. More than 80% of one-year-olds received inoc­u­la­tions against child­hood dis­eases in 2004.

Cur­rently, Turkey has a pop­u­la­tion of nearly 79 mil­lion, mean­ing it expe­ri­enced a total growth of 1.2% in the past year. In com­par­i­son to the coun­tries surrounding it, this is a rapidly increas­ing birth rate. It’s no stretch to say that Turkey is one of the lead­ing phar­ma­ceu­ti­cal mar­kets in the world, burst­ing at the seams with pos­si­bil­i­ties.

To help you work your way into this teem­ing mar­ket, we at CPC have devel­oped a sys­tem­atic part­ner search process to iden­tify your best-fit­ting part­ner in only 10–12 weeks.

The CPC approach will allow you to save time on the ‘get­ting-to-know-you’ meet­ings with pos­si­ble part­ners, as well as cut down on your travel costs and make you feel confident that you have the best part­ner for sales growth. To ana­lyse the Turk­ish mar­ket specif­i­cally, we use a SWOT analy­sis, which always offers many inter­est­ing out­comes. Despite its risks, the Turk­ish mar­ket is loaded with growth and poten­tial.

CPC Press Releases on Turkey:

Turkey – TRIUMPH country